Abstracts tagged "Biologic agents"

Abstract Number: 1107 • 2015 ACR/ARHP Annual Meeting
Inhibition of B Cell Activation and Plasma Cell Differentiation By Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22
Natalia V. Giltiay¹, Geraldine L. Shu², Anthony Shock³ and Edward A. Clark^1,2, ¹Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, ²Department of Immunology, University of Washington, Seattle, WA, ³UCB Pharma, Slough, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by B cell hyperactivity and production of autoantibodies. Treatment of patients with moderate-to-severe SLE with epratuzumab, a humanized…
Abstract Number: 1658 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Factor Status Affects the Efficacy of First Biological Treatment in RA
Yoshikazu Ogawa¹, Nobunori Takahashi², Koji Funahashi², Shuji Asai³, Toki Takemoto³, Tatsuo Watanabe³, Nobuyuki Asai², Naoki Ishiguro⁴ and Toshihisa Kojima², ¹orthopedic surgery, Nagoya University Hospital, Nagoya, Japan, ²Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ³Nagoya University Hospital, Nagoya, Japan, ⁴Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Rheumatoid factor (RF) is considered an important factor in diagnosing rheumatoid arthritis (RA). The association between the treatment efficacy of biological agents and RF…
Abstract Number: 2765 • 2015 ACR/ARHP Annual Meeting
Long-Term Retention Rate of First Biologics in Patients of Age over 75 Years with Rheumatoid Arthritis in Japanese Clinical Practice: Results from the Multicenter Biologic Registry
Masatoshi Hayashi¹, Toshihisa Kanamono², Hiroyuki Matsubara³, Toshihisa Kojima⁴, Koji Funahashi⁵, Nobunori Takahashi⁴ and Naoki Ishiguro⁶, ¹Department of Orhtopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ²Reumatology, Nagano Red Cross Hospital, Nagano, Japan, ³Department of Orthopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ⁴Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁵Nagoya University, Nagoya, Japan, ⁶Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: The objective of this report was to clarify and compare the retention rate of first biologics used to treat elderly Japanese patients with rheumatoid…
Abstract Number: 505 • 2015 ACR/ARHP Annual Meeting
Comparative Effectiveness and Time to Response Among Abatacept, Adalimumab, Certolizumab, Etanercept, Infliximab, Rituximab and Tocilizumab in a Real World Routine Care Registry
Yusuf Yazici¹, Hannah Bernstein¹ and Christopher Swearingen², ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Pediatrics & Biostatistics, University of Arkansas, Little Rock, AR
Background/Purpose: With the availability of multiple biologic agents, each with different modes of action, use of real world registries provide the manner in which to…
Abstract Number: 1108 • 2015 ACR/ARHP Annual Meeting
Epratuzumab, a Monoclonal Antibody Targeting CD22 on B Cells, Stimulates the Phosphorylation of Upstream Inhibitory Signals of the B Cell Receptor
Simon Lumb¹, Sarah J. Fleischer², Capucine Daridon², Alison Maloney¹, Anthony Shock¹ and Thomas Dorner², ¹UCB Pharma, Slough, United Kingdom, ²Charité University Medicine Berlin, CC12, Dept. Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Center Berlin (DRFZ), a Leibniz Institute, Berlin, Germany
Background/Purpose: Epratuzumab, a humanized monoclonal antibody targeting CD22, is currently in phase 3 clinical trials in patients with systemic lupus erythematosus (SLE). Previous work suggests…
Abstract Number: 1670 • 2015 ACR/ARHP Annual Meeting
Rapidity of Therapeutic Response of Biologics Compared to Methotrexate Monotherapy in Early RA: A Network Meta-Analysis
Raveendhara R. Bannuru, Mikala Osani, Anbuselvan Dharmarajan, Elizaveta Vaysbrot and Timothy E. McAlindon, Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: Rapidity of onset of therapeutic efficacy may be critically important in the management of early RA and may reduce long-term impact of the disease.…
Abstract Number: 2777 • 2015 ACR/ARHP Annual Meeting
Drug Retention Rates of Biologic Monotherapies for Patients with Rheumatoid Arthritis Receiving TNF Inhibiting Fusion Protein Agent and Antibody Agent; From Multicenter Registry in Japan
Hiroyuki Matsubara¹, Masatoshi Hayashi², Nobunori Takahashi³, Toshihisa Kojima³, Koji Funahashi³ and Naoki Ishiguro⁴, ¹Department of Orthopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ²Department of Orhtopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ³Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁴Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: In general, drug retention rate reflects the effectiveness and tolerability of the drug. TNF inhibitors include fusion protein agent such as etanercept (ETN) and…
Abstract Number: 544 • 2015 ACR/ARHP Annual Meeting
IL-6 May Have an Important Role in the Resistance to Anti-TNF Therapies of Human T-Lymphotropic Virus Type 1 (HTLV-1) Positive Rheumatoid Arthritis (RA) Patients; HTLV-1 Infected Cells Activate the Inflammatory Responses of RA Synovial Fibroblasts
Kunihiko Umekita¹, Shunichi Miyauchi¹, Kazuyoshi Kubo¹, Kazumi Umeki¹, Hajime Nomura¹, Mao Komura¹, Koushou Iwao¹, Ichiro Takajo¹, Yasuhiro Nagatomo¹, Toshihiko Hidaka² and Akihiko Okayama¹, ¹Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan, ²Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan
Background/Purpose: We reported that human T-lymphotropic virus type 1 (HTLV-1) positive patients with rheumatoid arthritis (RA) had higher inflammation and greater resistance to anti-TNF treatment…
Abstract Number: 1205 • 2015 ACR/ARHP Annual Meeting
The Spectrum of Early RA Practice Across the Globe: Results from a Multinational Cross Sectional Survey
Elena Nikiphorou¹, James Galloway^2,3, Piet L van Riel⁴, Andrew Östör⁵, Glenn Haugeberg^6,7, Feride Gogus^8,9, Markku Kauppi¹⁰, Yusuf Yazici¹¹ and Tuulikki Sokka-Isler¹², ¹Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Academic Department of Rheumatology, King´s College London, London, United Kingdom, ³King's College Hospital, Department of Rheumatology, London, London, United Kingdom, ⁴Scientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, Netherlands, ⁵Addenbrooke's Hospital, Cambridge, United Kingdom, ⁶Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway, ⁷Head of the Department of Rheumatology, Martina Hansens Hospital, Bærum, Norway, ⁸University of Gazi, Ankara, Turkey, ⁹Gazi University, Faculty of Medicine, Ankara, Turkey, ¹⁰Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ¹¹Rheumatology, Hospital for Joint Diseases and Medicine, NYU Langone Medical Centre, New York, NY, ¹²Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Early diagnosis & treatment are crucial to the management of rheumatoid arthritis (RA). Despite this, the approach to early RA management appears to be…
Abstract Number: 1676 • 2015 ACR/ARHP Annual Meeting
Systematic Review and Network Meta-Analysis of Combination Treatments in Disease Modifying Anti-Rheumatic Drug Experienced Patients with Severe Rheumatoid Arthritis: Analysis of American College of Rheumatology Criteria Scores 20, 50, and 70: An Update
Michelle E. Orme¹, Charles Hawes² and Stephen A. Mitchell³, ¹ICERA consulting UK, Swindon, United Kingdom, ²Pfizer UK, Surrey, United Kingdom, ³Abacus International UK, Bicester, United Kingdom
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (DMARDs) in combination with conventional DMARDs provide patients with severe rheumatoid arthritis (RA) and an inadequate response to conventional DMARDs…
Abstract Number: 2778 • 2015 ACR/ARHP Annual Meeting
Abatacept-Treated Rheumatoid Arthritis Patients Have Better Drug-Survival Rate When Abatacept Is the First or Second Line Biologic Agent with an Excellent Overall Safety Profile: A Single Center Experience
Irini Flouri¹, Argyro Repa², Antonis Fanouriakis², Nikolaos Kougkas², Ioannis Papalopoulos², Eleni Kampouraki², Dimitrios Boumpas³, Nestor Avgoustidis², George Bertsias² and Prodromos Sidiropoulos², ¹Rheumatology, Clinical Immunology, Allergy, University of Crete, Medical School, University Hospital, Heraklion, Greece, ²Rheumatology, Clinical Immunology, and Allergy, University of Crete, Medical School, University Hospital, Heraklion, Greece, ³Biomedical Research Foundation, Academy of Athens, Athens, Greece
Background/Purpose: Long-term prospective observational studies are complementary to controlled clinical trials in exploring the effectiveness and safety of biological therapies in rheumatoid arthritis (RA). We…
Abstract Number: 575 • 2015 ACR/ARHP Annual Meeting
Predictive Factors for Achieving Low Disease Activity at 52 Weeks after Switching from Tumor Necrosis Factor Inhibitors to Abatacept: Results from a Multicenter Observational Cohort Study of Japanese Patients
Toshihisa Kojima¹, Nobunori Takahashi¹, Koji Funahashi¹, Shuji Asai², Toki Takemoto², Nobuyuki Asai³, Tatsuo Watanabe², Naoki Ishiguro⁴ and TBCR Study Group, ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Nagoya University Hospital, Nagoya, Japan, ³Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁴Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: : Currently, there is no clarity regarding which biologic to switch to when patients fail to respond to TNF inhibitors (TNFis). Detailed information for…
Abstract Number: 1222 • 2015 ACR/ARHP Annual Meeting
The Risk of Tuberculosis (TB) in Rheumatoid Arthritis Patients Treated with TNF Inhibitors and the Safety of Resuming Biologic Dmards for Patients Who Developed TB after Anti-TNF Treatment
Soo-Kyung Cho¹, Dam Kim¹, Hye-Jin Jeong², Il Woong Sohn², Soyoung Won³, Minkyung Han³, Jiyoung Lee³, Eun Jin Jang⁴, Sang-Cheol Bae¹ and Yoon-Kyoung Sung¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Information Statistics, Andong National University, Andong-si, South Korea
Background/Purpose: The association between TNF inhibitor (TNFI) treatment and the development of tuberculosis (TB) has been confirmed through several observational studies. Current guidelines strongly recommend…
Abstract Number: 2051 • 2015 ACR/ARHP Annual Meeting
Risk for Lower Intestinal Perforations in RA Patients Treated with Tocilizumab in Comparison to Treatment with TNF Inhibitors, Rituximab, Abatacept or Conventional Synthetic Dmards
Anja Strangfeld¹, Adrian Richter², Peter Herzer³, Karin Rockwitz⁴, Winfried Demary⁵, Martin Aringer⁶, Angela Zink⁷ and Joachim Listing⁸, ¹Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Rheumatologist, Scientific Advisory Board, München, Germany, ⁴Rheumatologic Practice, Goslar, Germany, ⁵Rheumatologist, Hildesheim, Germany, ⁶Rheumatology, Medicine III, University Clinical Center, Technical University Dresden, Dresden, Germany, ⁷Epidemiologie, Deutsches Rheuma-Forschungszentrum, Berlin, Germany, ⁸Epidemiology, DRFZ, Berlin, Germany
Background/Purpose: Interleukin-6 has a direct protective effect on intestinal cells. Although several cases of lower intestinal perforations (LIP) were reported in clinical trials of tocilizumab…
Abstract Number: 2844 • 2015 ACR/ARHP Annual Meeting
Secukinumab Reduces the Burden of Nail and Skin Disease in Patients with Psoriasis and Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies
Alice B. Gottlieb¹, Kristian Reich², Zailong Wang³, Marina Milutinovic⁴ and Shephard Mpofu⁴, ¹Dermatology, Tufts Medical Center, Boston, MA, ²Dermatologikum Hamburg and Georg-August-University Göttingen, Hamburg, Germany, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Nail psoriasis is associated with decreased finger mobility and pain in patients (pts) with moderate to severe plaque psoriasis and psoriatic arthritis (PsA).1,2 Secukinumab,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].